))
Dermatology Edition: Top Headlines for Week of October 30, 2023
Manage episode 407442252 series 3560281
Indhold leveret af Healio. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Healio eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more. Read the full coverage here:
FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis
Roflumilast foam improves quality of life in patients with seborrheic dermatitis
Opzelura effective, well tolerated in children aged at least 2 years with atopic dermatitis
Treatment for onychomycosis prescribed at only 20% of visits, impacting quality of life
Study: Important to weigh berdazimer gel benefits vs. risks in molluscum contagiosum
References:
Calvi IP, et al. Pediatr Dermatol. 2023;doi:10.1111/pde.15419.
Chu D. et al. Poster. Effect of roflumilast foam 0.3% on quality of life in patients with seborrheic dermatitis: patient-reported outcomes from the STRATUM phase III trial. Presented at: AMCP Nexus; Orlando.
Peck GM, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6770.
Press Release
120 episoder
Del
